Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-22-101064
Filing Date
2022-04-11
Accepted
2022-04-11 08:57:59
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFA14A d339320ddefa14a.htm DEFA14A 29214
2 GRAPHIC g339320g39f01.jpg GRAPHIC 4287
3 GRAPHIC g339320g86t85.jpg GRAPHIC 16549
4 GRAPHIC g339320na3.jpg GRAPHIC 2378
5 GRAPHIC g339320na4.jpg GRAPHIC 2840
6 GRAPHIC g339320nanew.jpg GRAPHIC 28663
7 GRAPHIC g339320snap4004.jpg GRAPHIC 809
  Complete submission text file 0001193125-22-101064.txt   107473
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38997 | Film No.: 22818576
SIC: 2834 Pharmaceutical Preparations